Zhongchao Inc. reports developments as a Cayman Islands holding company whose PRC operating entities provide platform-based healthcare information, education, training, patient management, and internet healthcare services in China. Its updates center on cancer and major-disease services, including the MDMOOC professional education platform, Zhongxin patient management programs, Zhixun Internet Hospital, and Sunshine Health Forums.
Recurring news themes include patient aid and medication assistance projects, disease management models for oncology and autoimmune conditions, healthcare professional education platforms, content partnerships for cancer education, and ordinary-share consolidations tied to Nasdaq listing compliance for ZCMD Class A ordinary shares.
Zhongchao Inc. (NASDAQ: ZCMD) has partnered with the Beijing Bethune Charitable Foundation and BeiGene to conduct a one-year project focused on leukemia diagnosis and treatment education. Launched in December 2020, the initiative will run until December 2021, offering over 100 academic exchange sessions to more than 10,000 clinicians. The program aims to improve practices in leukemia treatment by providing advanced training, expert-led discussions, and case study presentations, involving over 400 experts and 255 case studies.
Zhongchao Inc. (NASDAQ: ZCMD) has announced the launch of a new patient management service targeting tumor and rare disease patients through its subsidiary, Shanghai Zhongxin Medical Technology. The service aims to improve treatment outcomes by leveraging the Company's healthcare platforms, which provide training and information to healthcare professionals and the public. The global cancer market is significant, with around 19.29 million new cases reported in 2020, of which 4.57 million occurred in China. Zhongchao aims to enhance patient engagement to drive better treatment results.
Zhongchao Inc. (NASDAQ: ZCMD) reported its fiscal year 2020 results, highlighting a 20.9% revenue increase to $17.99 million compared to 2019. Gross profit rose by 16.1% to $11.87 million, while gross margin decreased to 66.0%. Operating income was up 23.3% to $4.49 million, with net income at $4.46 million, an increase of 10.2%. Despite a slight drop in earnings per share to $0.183, the company remains optimistic about future growth driven by patient-aid projects and new educational initiatives.
On March 17, 2021, Zhongchao Inc. (NASDAQ: ZCMD) announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited. This partnership will continue the 'Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals' program, aimed at improving doctors' capabilities in treating pulmonary hypertension. The initiative engaged over 200 experts in 2020, training around 10,000 clinicians. The company anticipates increased participation in 2021, fostering further growth in rare disease education.
Zhongchao Inc. (NASDAQ: ZCMD) co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment, collaborating with key medical associations. The Company highlighted its 2020 initiative, training over 500,000 healthcare professionals in China on updated liver cancer treatment guidelines. Jia Fan, a leading expert in liver cancer, emphasized the importance of adapting guidelines to enhance patient outcomes. CEO Weiguang Yang noted ongoing updates to these guidelines in response to rapid advancements in the field, underscoring Zhongchao's commitment to effective implementation for healthcare practitioners.
Zhongchao Inc. (NASDAQ: ZCMD) reported robust financial results for the first half of 2020, with revenues up 21.1% to $8.46 million and operating income rising 49.2% to $1.88 million, driven by patient-aid projects and COVID-19 training courses. However, net income attributable to shareholders fell 15.7% to $1.46 million due to reduced government subsidies and higher taxes, leading to a decline in earnings per share from $0.08 to $0.06. Overall, the company maintains a positive outlook, expecting continued revenue growth in the second half of 2020.
Zhongchao Inc. (NASDAQ: ZCMD) announced its continued partnership with the European Wound Management Association (EWMA) to deliver advanced workshops on wound care and rehabilitation in China. Starting on September 11, 2020, the workshops will provide physicians with a comprehensive curriculum, including a core and advanced course in wound management. Participants can earn an EWMA certificate upon completion. In recognition of COVID-19 health workers, Zhongchao is waiving fees for eligible physicians.
Zhongchao Inc. (NASDAQ: ZCMD) announced a partnership with the China Association of Health Promotion and Education to develop live interactive courses aimed at promoting the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in China. These courses are designed to enhance the clinical practices of healthcare professionals by providing practical guidelines on COPD management. Available on the MDMOOC platform, the programs feature diverse educational formats, including articles, case studies, and expert interviews. This initiative aims to increase awareness and improve patient outcomes related to COPD in the region.
Zhongchao Inc. (NASDAQ: ZCMD) announced the renewal of its contract with Johnson & Johnson (China) Limited, extending their partnership in healthcare services, training, and education. This collaboration, ongoing since 2017, capitalizes on Johnson & Johnson's significant presence in the Chinese market, including multiple R&D centers and manufacturing facilities. As the Chinese healthcare sector continues to grow, Zhongchao aims to leverage its relationship with J&J to capture market opportunities.
Zhongchao Inc. (NASDAQ: ZCMD) has partnered with the China Health Promotion Association and major pharmaceutical companies to launch a multi-year online education project focused on primary liver cancer. The initiative aims to implement national treatment guidelines and enhance professionals' knowledge in screening, diagnosis, and management of liver cancer. Since its launch in March 2020, over 145,000 medical professionals have participated in 12 training sessions, with more planned for the future.